Biotech Values

[DewDiligence]

Re: Investing in ADC companies

Don’t fall for companies that claim their conjugate is unique/different. Yeah it might make a difference but it isn’t nearly as important as the target.

I would argue that the reverse might be true—i.e. that the targets for applying ADCs tend to be pretty well know, but the different linker technologies can make a big difference in safety.

Better safety allows higher dosing, which in turn increases efficacy. ADCs are essentially chemotherapy agents with a twist that enables higher dosing without the concomitant toxicity. There are many cancer indications where traditional chemo remains the SoC that ought to be ripe for penetration by ADCs.

p.s. I do not own any ADC companies directly, but I’m long PFE (SGEN).